Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19433989)

  • 1. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer.
    Custodio AB; González-Larriba JL; Bobokova J; Calles A; Alvarez R; Cuadrado E; Manzano A; Díaz-Rubio E
    J Thorac Oncol; 2009 Jul; 4(7):891-910. PubMed ID: 19433989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of adjuvant chemotherapy in NSCLC (stages I to III).
    Coleman MH; Bueno R
    Surg Oncol Clin N Am; 2011 Oct; 20(4):757-67. PubMed ID: 21986270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
    Ikeda N; Nagase S; Ohira T
    Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment of non-small-cell lung cancer: how do we improve the cure rates further?
    Wozniak AJ; Gadgeel SM
    Oncology (Williston Park); 2007 Feb; 21(2):163-71; discussion 171, 174, 179-82. PubMed ID: 17396481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
    Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise.
    Azzoli CG; Park BJ; Pao W; Zakowski M; Kris MG
    J Thorac Oncol; 2008 Jan; 3(1):84-93. PubMed ID: 18166846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC; Timsit JF; Couraud S; Merle P; Moro-Sibilot D; Perol M; Mastroianni B; Souquet PJ; Girard N; Jeannin G; Romand P; Chatellain P; Vesin A; Brambilla C; Brambilla E
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection.
    Broët P; Camilleri-Broët S; Zhang S; Alifano M; Bangarusamy D; Battistella M; Wu Y; Tuefferd M; Régnard JF; Lim E; Tan P; Miller LD
    Cancer Res; 2009 Feb; 69(3):1055-62. PubMed ID: 19176396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
    Heon S; Johnson BE
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
    Wakelee H; Dubey S; Gandara D
    Oncologist; 2007 Mar; 12(3):331-7. PubMed ID: 17405898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
    J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer.
    Visbal AL; Leighl NB; Feld R; Shepherd FA
    Chest; 2005 Oct; 128(4):2933-43. PubMed ID: 16236970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of adjuvant chemotherapy in early-stage and locally advanced non-small cell lung cancer.
    Shapiro M
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS42-5. PubMed ID: 22614965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer.
    Horn L; Sandler AB; Putnam JB; Johnson DH
    J Thorac Oncol; 2007 May; 2(5):377-83. PubMed ID: 17473651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant chemotherapy for resectable non-small cell lung cancer (NSCLC)].
    Nakajima E; Katou H
    Kyobu Geka; 2008 Jan; 61(1):4-8. PubMed ID: 18186265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy for non-small cell lung cancer.
    Pinder-Schenck M; Bepler G
    Minerva Chir; 2009 Dec; 64(6):611-28. PubMed ID: 20029358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The coming of age of molecular tumor profiling.
    Antonoff MB; D'Cunha J
    Semin Thorac Cardiovasc Surg; 2011; 23(1):8-9. PubMed ID: 21807290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.